U.S. Direct Anterior Approach (Total Hip Replacement) Market in ACS Market Research Report, by U.S. Total Hip Replacement Market, U.S. Total Hip Replacement by DAA, U.S. Total Hip Replacement Market for DAA by ACS - Global Forecast Till 2027

U.S. Anterior Approach- Summary

The U.S. direct anterior approach (total hip replacement) in ASC market, as per the reports of Market Research Future (MRFR), is touted to reach the valuation of U.S.D 1,793.2 million by 2023. Growing at a staggering CAGR of 13.6% during the forecast period (2017-2023), this remedial procedure could prove beneficial for the healthcare market and its dependents. The market increase can be triggered further by technological advents and high mortality rate in coming years.

Worldwide urbanization has led to a paradigm shift in the human behavioral pattern. Coupled with a sedentary lifestyle, this transferal has affected many adversely resulting in the emergence of osteoarthritis as a bane. According to the reports of The American Joint Replacement Registry, in 2016, around 70% of the hip replacement surgery patients suffer from osteoarthritis. The daunting percentage, translated to numbers, could rise to 78 million by the end of 2040. Osteoarthritis’ prevalence can steer the market of hip replacement to a commendable height.

Rising mortality percentage inflates the geriatric population, along with the need for surgeries such as total hip replacement. Published in 2015, reports from the Geriatric Orthopaedic Surgery & Rehabilitation journal pins down the average age for primary total hip arthroplasty (THA) at 65. This number becomes intimidating if read along with the reports of United States Census Bureau tagging 46.2 million U.S. citizens nearing the age of 65 and above. The elderly population is more susceptible to osteoarthritis, which the market could interpret as a favorable condition for expansion.

However, the market is not without its challenges. Total hip replacement incurs a considerable cost, and the surgical procedure is complicated, which could prevent the market from reaching its expected growth rate.

Industry Trends:

Demand for minimally invasive surgeries are on the rise, and growing awareness regarding it can prove profitable for the market. Various U.S. companies have now increased their research and development (R&D) expenditure and coming up with procedures with short incisions, reduced muscle damage and quicker recovery time. Zimmer Biomet, increasing the R&D expenditure from 4.5% to 4.7% in 2017, has transpired into an expansion of their portfolio and be considered exemplary.

Segmentation:

The U.S. direct anterior approach (DAA) in ASC market can be segmented by U.S. total hip replacement, U.S. total hip replacement by DAA, and U.S. total hip replacement for DAA by ambulatory surgical centers (ASC). The total hip replacement market includes direct anterior approach, lateral approach, and posterior approach.

Shorter hospital duration and cost-effective procedures compared to hospitals have given rise to the demand for ASC in the U.S. and is expected to inflate further during the forecast period.

Market Analysis:

The presence of significant market mavens such as Johnson and Johnson Services Inc. (DePuy Synthes), Stryker, Zimmer Biomet, and Smith & Nephew have made the U.S. market competitive with all of them vying for the crest. By remaining abreast with the latest technologies, these companies are introducing procedures to revamp the market and expand it exponentially.

U.S. Direct Anterior Approach (Total Hip Replacement) Market in ACS: Competitive Landscape

Smith & Nephew, Zimmer Biomet, Stryker and Johnson & Johnson Services Inc. collectively accounted for more than 79.8% of the market share of the U.S. Direct Anterior Approach (Total Hip Replacement) Market in 2017. These companies continue to retain their strong market presence through expansions, mergers and acquisitions, and extensive product portfolio.

In 2017, Johnson & Johnson Services, Inc. (DePuy Synthes) was the leading player in the market and accounted for more than ~33.3% of market share. The large share of the company is attributed to the high demand for hip reconstruction products. Moreover, this company has a strong sales and distribution network. Along with that, this company also provides after sales services which play a major role in the satisfaction of the customers.

Zimmer Biomet held the second position in the market and accounted for more than ~26.6% of the market share. Zimmer Biomet has a vast product portfolio in the total hip replacement industry. The company also has a wide geographic presence as it operates in various countries all around the world. It has a significant presence in North America, Europe, and the Middle East and Africa, with commercial, manufacturing, and research facilities in more than one dozen countries.

Stryker held the third position in terms of market share, in 2017 and accounted for more than ~11.8% of the market share. The company follows the strategy of launching new products and focuses on the acquisition and collaboration with an aim to minimize the competition. For instance, in 2018, Stryker launched Trident Acetabular System, made up of its tritanium in growth technology. Tritanium mimics the porous bone and thus enhances cell attachment and proliferation which eventually promotes long-term biologic fixation.

Smith & Nephew acquired the fourth spot in the market. The company is well known for its sports medicine, trauma, orthopedic reconstruction, and advanced wound management. In 2015, Smith & Nephew announced the acquisition of Blue Belt Holdings, Inc. for USD 275 million, making the company secure a leading position in the fast-growing area of orthopedic robotics-assisted surgery.

New product developments along with the strategy of acquisitions is a key focus area for players as the demand for more effective products continues to grow. Majority of the companies have adopted the strategy of acquisitions and product launches for the market development.